Isobaric 2-chloroprocaine — Competitive Intelligence Brief

Isobaric 2-chloroprocaine (Isobaric 2-chloroprocaine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic (ester). Area: Anesthesia.

marketed Local anesthetic (ester) Voltage-gated sodium channels Anesthesia Small molecule

Target snapshot

Isobaric 2-chloroprocaine (Isobaric 2-chloroprocaine) — Centre Hospitalier Universitaire Saint Pierre. Isobaric 2-chloroprocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Isobaric 2-chloroprocaine TARGET	Isobaric 2-chloroprocaine	Centre Hospitalier Universitaire Saint Pierre	marketed	Local anesthetic (ester)	Voltage-gated sodium channels
Bupivacaine 0.25% with Epinephrine	Bupivacaine 0.25% with Epinephrine	Holy Cross Hospital, Florida	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels
guided injection of mepivacaine	guided injection of mepivacaine	Complejo Hospitalario Universitario de Granada	marketed	Local anesthetic (amide)	Voltage-gated sodium channels
Bupivacaine + Sufentanil epidural	Bupivacaine + Sufentanil epidural	Charles University, Czech Republic	marketed	Local anesthetic + opioid combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (sufentanil)
Bupivacaine with intrathecal morphine	Bupivacaine with intrathecal morphine	Centre Hospitalier Universitaire Vaudois	marketed	Local anesthetic with intrathecal opioid	Voltage-gated sodium channels (bupivacaine); mu-opioid receptors (morphine)
Bupivacaine 0.125%	Bupivacaine 0.125%	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Local anesthetic	Voltage-gated sodium channels
Bupivacaine 0.5% , Dexamethasone	Bupivacaine 0.5% , Dexamethasone	Sisli Hamidiye Etfal Training and Research Hospital	marketed	Local anesthetic with corticosteroid adjuvant	Voltage-gated sodium channels (bupivacaine); glucocorticoid receptor (dexamethasone)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic (ester) class)

1. Sintetica SA · 4 drugs in this class
2. Centre Hospitalier Universitaire Saint Pierre · 1 drug in this class
3. Nova Scotia Health Authority · 1 drug in this class
4. American Genomics, LLC · 1 drug in this class
5. University of Miami · 1 drug in this class
6. Wenzhou Medical University · 1 drug in this class
7. Oregon Health and Science University · 1 drug in this class